Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.40 |
| ▸ | MMP7 | P09237 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7055490 | 0.88 | MMP8 (0.40) | MMP3MMP8POLB | |
| SCHEMBL7059663 | 0.88 | MMP8 (0.42) | MMP3MMP8MMP1MMP7MMP9 | |
| SCHEMBL7053151 | 0.86 | SMN1; SMN2 (0.34) | MMP1MMP13POLBSMN1; SMN2RAB9A | |
| SCHEMBL7057216 | 0.85 | MMP8 (0.42) | MMP3MMP8MMP1MMP7MMP9 | |
| Hydrochloric Acid SCHEMBL7054481 | 0.82 | MMP8 (0.40) | MMP3MMP8MMP1MMP9MMP13 | |
| SCHEMBL7054506 | 0.81 | GAA (0.43) | MMP3MMP8MMP1MMP7MMP9 | |
| SCHEMBL7057731 | 0.79 | MMP9 (0.55) | MMP3MMP8MMP1MMP7MMP9 | |
| SCHEMBL7054271 | 0.78 | MMP3 (0.43) | MMP3MMP8MMP1MMP7MMP13 | |
| Hydrochloric Acid SCHEMBL7059703 | 0.78 | MMP8 (0.51) | MMP3MMP8MMP1MMP7MMP13 | |
| SCHEMBL7353809 | 0.78 | MMP8 (0.40) | MMP3MMP8MMP1MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |